Birken AG Report issue

For profit Phase 3
Founded: Niefern-Öschelbronn Germany (2012)
Status: Acquired by Amryt Research Limited (2016) → now Chiesi (2023)

Organization Overview

First Clinical Trial
2012
NCT00786994
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (2)

octenidine (1 trial)

oleogel-s10 (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Burns (Phase 3)

Keratosis (Phase 2)

Keratosis, Actinic (Phase 2)

Wounds and Injuries (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 2